RxSight(US:RXST) Prnewswire·2026-01-01 15:00Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving RxSight, Inc. and its executives [1] Group 1: Management Changes - RxSight announced the departure of its Chief Financial Officer, Shelley Thunen, who will remain until her successor is appointed or by January 31, 2026 [2] - The departure of Thunen was noted as surprising by financial services firm BTIG, especially given early signs of operational improvement and a recent management reshuffle [2] - The timing of these leadership transitions suggests ongoing commercial challenges for RxSight, potentially delaying a broader recovery into 2026 despite some recent progress [2] Group 2: Stock Performance - Following the announcement of Thunen's departure, RxSight's stock price fell by $1.22 per share, representing a decline of 9.98%, closing at $11.01 per share on December 23, 2025 [3]